K **:** ; H ; HFE;

I **:**

-

1 .

2 .

I

3 .

, . A

, ; C , 7.55– 4.24 .

4 .

5 .

-

6 .

, ,

. -

,

7,8 .

A

9 .

A H F E (*HFE*)

65%

10 .

HFE 6 11 . ,

HFE

282 12 .

, HFE C282

B -

.

j **:**

: , 76 -

36 40

H , E H

E B C,

.

***Corresponding author:**
of Medicine, Menouýa University, Shebin Elkom City, Egypt, Tel: +201090365171; Fax: +20482181009; E-mail: ebadr2014@gmail.com

Received July 27, 2017; **Accepted** August 26, 2017; **Published** September 04 2017

Citation: , El-Hawy El-dean SRIS, El Tantawy El Sayed I

	Group 1 (n=76) Mean ± SD	Group 2 (n=51) Mean ± SD	t- test	P value
Age (years)	7.55 Ñ 4.24	8.31 Ñ 4.19	0.996	>0.05
Gender Male No % Female No %	 41 53.9% 35 46.1%	 29 56.9% 22 43.1%	g^2=0.10	>0.05
Weight in Kg	23.93 Ñ 11.73	28.76 Ñ 13.25	2.158	<0.05*
Height (cm)	115.68 Ñ 25.84	126.15 Ñ 25.54	2.249	<0.05*
BMI	17.04 Ñ 2.87	16.93 Ñ 1.62	0.236	>0.05
Splenectomy Positive No % Negative No %	 28 36.8% 48 63.2%	 00 00% 51 100%	g^2=24.10	<0.001**

Table 1: Comparison between the studied groups regarding demographic and clinical data in patient and control.

	Group 1 (n=76) Mean ± SD	Group 2 (n=51) Mean ± SD	t- test	P value
AST (IU/L)	98.53 Ñ 100.89	28.07 Ñ 4.68	4.977	<0.001**
ALT (IU/L)	133.15 Ñ 283.20	28.11 Ñ 3.86	2.645	<0.01**
Creatinine (mg/dl)	0.69 Ñ 1.08	0.96 Ñ 1.70	1.064	>0.05
Urea (mg/dl)	31.88 Ñ 8.52	30.68 Ñ 5.81	0.873	>0.05
ALP (IU/L)	362.73 Ñ 85.32	96.01 Ñ 9.14	6.618	<0.001**
Ferritin (ng/ml)	2334.27 Ñ 1779.49	97.78 Ñ 25.33	8.963	<0.001**
Iron (ug/dl)	195.17 Ñ 71.19	81.47 Ñ 10.31	11.311	<0.001**
TIBC (ug/dl)	144.27 Ñ 79.84	293.80 Ñ 25.65	12.919	<0.001**
Hepcidin (ng/ml)	66.90 Ñ 14.47	76.72 Ñ 16.53	18.931	<0.001**
WBCs (Ĭ 10¡/L)	22.83 Ñ 25.67	7.03 Ñ 2.36	4.377	<0.001**
RBCs (Ĭ 10^6/L)	2.83 Ñ 0.59	4.73 Ñ 0.34	17.317	<0.001**
Hb (gm/dl)	7.77 Ñ 1.76	11.72 Ñ 1.27	13.266	<0.001**
Platetets count (Ĭ 10¡/L)	409.17 Ñ 269.53	326.27 Ñ 83.94	2.126	<0.05*
MCV (õm^3)	78.49 Ñ 6.5	74.6 Ñ 8.8=52	2.907	<0.05*
MCH (pg)	27.58 Ñ 3.34	24.87 Ñ 2.84	4.680	<0.01**
RDW (%)	35.07 Ñ 3.47	34.14 Ñ 0.52	6.166	<0.001**

Table 2: Comparison between the studied groups regarding laboratory data, iron related parameters in patient and control.

.

AA AG GG (4). (. 45%,

F , A

, IBC , *HFE* -

.

AA, AG GG

HFE (C282) %

2500 /

AA AG

GG (5).

D

15 .

,

, -

(BI),

,

, 16 .

17 .

1800562

HFE

I

.

I

A A HFE (C282)

.

Citation:

C282 , (H63D) I -
(65C) 18 . AA -3 ( )3 - I 5 (A)-3 (

,
C282

19 .

I . 20 , 2
81 *C282Y* 1800562
. E . 21 , . 22
. 23 ,
.

I
C282Y 1800562 . ,
. 24 *HFE*
1800562 .

I -
I AA
AG GG . A ,
AA
.

A
287.2 6
C282 25 .

Citation:

Acknowledgement

We acknowledge the central laboratory unit, faculty of Medicine, Menouýa University for providing us with the necessary instruments for completion of the study.

Ethical Approval

Research involving Human Participants. The study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent, and the Ethics Committee of Faculty of Medicine, Menouýa University approved the study protocol.

References

1. Chiruka S, Darbyshire P (2011) Management of thalassaemia. Paediatr Child Health 21: 353-356.
2. Rund D, Rachmilewitz E (2005) Thalassemia. N Engl J Med 353: 1135-1146.
3. Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5: 11.
4.